drug interactions with glp-1 mechanism of action of analogues, DPP-IV inhibitors, and Interaction between drugs and GLP-1
Description
Treatment was stopped, and the patient was permanently withdrawn from the study
We caught up with Mather, who participated in the game changer session The Risks and Rewards of GLP-1 Agonists Beyond Diabetes at the 2025 American Physiology Summit in April
Waser, B., Rehmann, R., Sanchez, C., Fourmy, D
However, the incidence of other common adverse events, such as urinary tract infections, drug discontinuation due to adverse events, severe hypoglycemia, and severe adverse events, did not differ significantly between combination therapy and monotherapies (Fig
